On October 24, 2023 Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of targeted drugs for the treatment of cancer, reported that the company will report its financial results for the three months ended September 30, 2023 on Thursday, November 2, 2023 (Press release, Cellectar Biosciences, OCT 24, 2023, View Source [SID1234636294]). Management will also host a conference call with investors to discuss financial results and provide an overview focused on the Waldenstrom’s macroglobulinemia market and its lead product candidate, iopofosine I 131, at 8:30 am Eastern Time. Details for the call are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference call & Webcast Details:
Date: Thursday, November 2
Time: 8:30 am Eastern Time
Toll Free: 1-888-886-7786
International: 1-416-764-8658
Webcast: Click HERE
Call me: Click HERE

Participants may use the dial-in numbers above and be answered by an operator OR click Call me link for instant telephone access to the event. The Call me link will be made active 15 minutes prior to the scheduled start time.